AstriVax
Recent Finacing
Grant
Recent Raise
$3.2M
AstriVax is a KU Leuven spin‑off developing a plug‑and‑play vaccine platform to produce thermostable, easy‑to‑manufacture prophylactic and therapeutic vaccines with reduced cold‑chain requirements and clinical-stage candidates.
Highlights
Focus Areas
Clinical Trials
Medical
Recent Investors
Financials
$35.8M
Total Raised
3
Funding rounds
9
Investors